Please login to the form below

Not currently logged in
Email:
Password:

melanoma drug

This page shows the latest melanoma drug news and features for those working in and with pharma, biotech and healthcare.

BMS' Yervoy picks up another indication in Europe

BMS' Yervoy picks up another indication in Europe

The EU green light will be welcomed news after BMS saw the big-selling melanoma drug flop in a head-to-head trial with Merck &Co’s Keytruda (pembrolizumab), which was ... melanoma is an outcome of BMS’s unyielding commitment to advancing treatments

Latest news

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    Novartis scores but Roche misses in melanoma trials. Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. ... indicates that the drugs could "transform the standard of care in the melanoma adjuvant setting".

  • BMS wins first US immuno-oncology paediatric licence BMS wins first US immuno-oncology paediatric licence

    The Food and Drug Administration (FDA) approved an expanded licence for Yervoy (ipilimumab) that will allow its use to treat unresectable or metastatic melanoma in patients aged 12 and older. ... led analysts at EvaluatePharma to predict that Merck

  • Opdivo tops Yervoy in adjuvant melanoma trial Opdivo tops Yervoy in adjuvant melanoma trial

    Opdivo tops Yervoy in adjuvant melanoma trial. BMS’nivolumab reduced the recurrence rate of melanoma compared to Yervoy. ... Opdivo (nivolumab) reduced the recurrence rate for patients with high-risk, advanced-stage melanoma who received the drug along

  • Novartis gets lung cancer OK for Tafinlar/Mekinist combo Novartis gets lung cancer OK for Tafinlar/Mekinist combo

    Novartis' cancer duo Tafinlar and Mekinist have been given the go-ahead in the EU as a treatment for non-small cell lung cancer (NSCLC), extending the use of the drug ... inhibitor - in combination with Tafinlar/Mekinist in melanoma patients, and also

  • Opdivo drives gain in BMS sales, but business revamp coming Opdivo drives gain in BMS sales, but business revamp coming

    Immuno-oncology drug Opdivo led the charge at Bristol-Myers Squibb in the third quarter with a three-fold hike in sales, despite its recent setback in first-line lung cancer. ... BMS' other growth products also contributed to the sales gains, with

More from news
Approximately 2 fully matching, plus 71 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics